TTK Healthcare (BOM:507747) ROCE %: 10.75% (As of Mar. 2026)


BOM:507747 TTK Healthcare Ltd BOM:507747
72 GF Score
Price ₹920.00
GF Value ₹1,452.29
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is TTK Healthcare ROCE %?

TTK Healthcare BOM:507747 +1.47% 72 ROCE % is 10.75% as of Mar. 2026. GuruFocus rates BOM:507747 with a GF Score™ of 72/100 and a GF Value™ of ₹1,452.29 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TTK Healthcare's annualized ROCE % for the quarter that ended in Mar. 2026 was 10.75%.

TTK Healthcare  (BOM:507747) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TTK Healthcare ROCE % Related Terms

TTK Healthcare ROCE % Historical Data

* Premium members only.

The historical data trend for TTK Healthcare's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TTK Healthcare ROCE % Chart

TTK Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.73 10.31 8.76 10.63 7.69

TTK Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.47 6.89 8.12 5.42 10.75
BOM:507747
72GF Score
TTK Healthcare Ltd BOM:507747
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TTK Healthcare ROCE % Calculation

TTK Healthcare's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=843.296/( ( (12811.867 - 2109.231) + (13287.425 - 2062.313) )/ 2 )
=843.296/( (10702.636+11225.112)/ 2 )
=843.296/10963.874
=7.69 %

TTK Healthcare's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1206.524/( ( (0 - 0) + (13287.425 - 2062.313) )/ 1 )
=1206.524/( ( 0 + 11225.112 )/ 1 )
=1206.524/11225.112
=10.75 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 10.75% mean?
TTK Healthcare (BOM:507747) has a ROCE % of 10.75% as of Mar. 2026.
Is TTK Healthcare's ROCE % too high?
TTK Healthcare's current ROCE % is 10.75%. The Drug Manufacturers industry median ROCE % is 7.03. TTK Healthcare's value of 10.75% is 52.9% above this industry median. Overall, TTK Healthcare has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTK Healthcare's ROCE % compare to LLY and JNJ?
TTK Healthcare's ROCE % of 10.75% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. TTK Healthcare's value of 10.75% is 52.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTK Healthcare's current ROCE % of 10.75% is 52.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTK Healthcare's current ROCE % is 10.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTK Healthcare stock overvalued right now?
Based on GuruFocus' analysis, TTK Healthcare (BOM:507747) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹1,452.29, compared to a current price of ₹920.00 — trading 36.7% below its estimated fair value. The current ROCE % is 10.75% and 52.9% above the Drug Manufacturers industry median of 7.03. TTK Healthcare's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TTK Healthcare (BOM:507747), the current ROCE % is 10.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TTK Healthcare (BOM:507747) Overvalued in 2026?

Based on GuruFocus' analysis, TTK Healthcare stock appears to be undervalued. The current stock price of ₹920.00 is trading 36.7% below its estimated GF Value™ of ₹1,452.29. GuruFocus considers TTK Healthcare to be Significantly Undervalued.

Key valuation signals for BOM:507747:

  • ROCE %: 10.75%
  • GF Value™: ₹1,452.29 vs. price of ₹920.00 (36.7% below fair value)
  • GF Score™: 72/100 with 1 warning sign
  • Industry Position: 52.9% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:507747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TTK Healthcare Business Description

Other Exchanges TTKHLTCARE:India
Address No. 6, Cathedral Road, Chennai, TN, IND, 600 086
TTK Healthcare Ltd is an Indian pharmaceutical company. The company's operating segment includes Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods Division, and Others. Its Animal Welfare segment includes products for both Human and Veterinary use. The Consumer Products comprises of marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners and others. Protective Devices comprises of manufacturing and marketing of Male Contraceptives and other allied products. It generates maximum revenue from the Pharmaceuticals segment. Geographically, it derives a majority of revenue from India.
72GF Score

Get the complete analysis for BOM:507747

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹920.00
Price
₹1,452.29
GF Value